FORM 8.5 (EPT/RI) Amendment PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose relevant…
WEXFORD, Pa. , Feb. 6, 2025 /PRNewswire/ — COEPTIS, Inc. (Nasdaq: COEP ) (the “Company” or “Coeptis”), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the successful closure of an additional $5.7 million in its final…
WEXFORD, Pa. , Jan. 30, 2025 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP ) (the “Company” or “Coeptis”), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is…
WEXFORD, Pa. , Jan. 23, 2025 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP ) (the “Company” or “Coeptis”), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited…
WEXFORD, Pa. , Jan. 22, 2025 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP ) (the “Company” or “Coeptis”), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it has regained compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”), as required…
WEXFORD, Pa. , Jan. 7, 2025 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP ) (the “Company” or “Coeptis”), a biopharmaceutical company focused on…
WEXFORD, Pa. , Dec. 27, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP ) (the “Company” or “Coeptis”), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it will proceed with a 1-for-20 reverse stock split (the “Reverse Split”) of its…
WEXFORD, Pa. , Dec. 26, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP ) (the “Company” or “Coeptis”), a biopharmaceutical company specializing in innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, proudly announces the completion of its…
WEXFORD, Pa. , Dec. 12, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the official launch of Coeptis Technologies, a new division aimed at diversifying and enhancing the company’s growth potential.
WEXFORD , Pa. , Dec. 3, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP ) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and…
This section of our website may contain dated or archived information that should not be considered current and may no longer be accurate. For the most up-to-date information about our company, please refer to our latest official communications and materials. Certain statements contained in our releases, events, and presentations that are not historical facts are forward-looking statements. These statements involve risks and uncertainties, including, but not limited to, the outcomes of research and development activities, results of preclinical and clinical studies, regulatory considerations, the impact of competitive products, product development and commercialization challenges, technological factors, and other risks inherent to our business. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date they are made, except as required by applicable law. This website may contain links to third-party websites for convenience. The inclusion of any such links does not imply endorsement of the content, products, or services offered by those third parties. We do not control and are not responsible for the content, accuracy, or functionality of any third-party websites.
© Copyright Coeptis Holdings, Inc. 2026
